Cellular therapy Peoria: what may help a sore joint

Why does it hurt more on some days?

A joint makes slippery fluid so its moving surfaces can glide against each other. Gentle movement spreads that fluid, while a long rest allows muscles and other soft parts to tighten. That's why the first steps after sitting may hurt more.

A busy day can press harder on an irritated joint, causing a deep ache, puffiness, or a quick sharp pain. Carrying groceries or walking farther than usual may explain a rough evening.

Weather bothers some people, but the day's work often tells you more.

What can I do at home today?

Ease back for a day, but don't remain in one chair from morning to night. Slow bending and straightening can keep the joint loose. If activity leaves it puffy, cover a cold pack with cloth and rest it there briefly. Gentle heat can loosen stiff muscles before you move.

Supportive shoes may reduce the load on an aching leg, and a cane may help when used safely. Simple strength work lets the muscles around the joint bear more weight.

Stop the exercise if it brings sharp pain or more swelling.

What could I try before surgery?

An exam may lead to exercise, a brace, medicine, or a talk about other choices. Regenerative treatments are non-surgical options for which a clinic spins your blood or marrow, then puts the saved liquid inside the aching joint.

PRP is made by spinning a small blood sample and saving liquid rich in platelets, the very small blood pieces used in healing. Concentrated PRP holds more of those blood pieces in the saved liquid.

These choices won't suit every joint, and your outcome can't be promised. Ask which liquid would be used, what risks apply, and how you'll judge any change.

Sources

1. A 2016 analysis of internet marketing found widespread direct-to-consumer promotion of unapproved stem cell interventions by businesses based in the United States - not only in countries with lax medical regulation - and concluded regulators must better oversee the marketplace.

   Turner L, et al. — Selling Stem Cells in the USA: Assessing the Direct-to-Consumer Industry. Cell Stem Cell, 2016. DOI: 10.1016/j.stem.2016.06.007.

2. A systematic analysis of 243 clinic websites offering stem cell therapies found routine use of hype language and inconsistent disclosure of the experimental or unproven status of what was being sold, with complementary and alternative medicine practitioners heavily represented.

   Murdoch B, et al. — Exploiting science? A systematic analysis of complementary and alternative medicine clinic websites' marketing of stem cell therapies. BMJ Open, 2018. DOI: 10.1136/bmjopen-2017-019414.

3. A 2019 JAMA research letter documented the credentials and scope of training of the physician and non-physician practitioners staffing US companies that market unproven stem cell procedures - many practise well outside the specialty their training covers.

   Fu W, et al. — Characteristics and Scope of Training of Clinicians Participating in the US Direct-to-Consumer Marketplace for Unproven Stem Cell Interventions. JAMA, 2019. DOI: 10.1001/jama.2019.5837.

4. FDA states in its consumer alert that the only FDA-approved stem cell products in the United States are blood-forming stem cells derived from umbilical cord blood, approved for disorders of the blood-forming system, and that NONE of these products - stem cells, stromal vascular fraction, umbilical cord blood, Wharton's jelly or amniotic fluid - has been approved for the treatment of any orthopedic condition, including osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain or shoulder pain.

   US Food and Drug Administration, Center for Biologics Evaluation and Research — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. , 2020.

5. The OARSI non-surgical management guideline evaluated 60 interventions with GRADE methodology and built its recommendations around core treatments - structured exercise, weight management and self-management education - for every patient with knee osteoarthritis, regardless of what else is added.

   Bannuru RR, et al. — OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage, 2019. DOI: 10.1016/j.joca.2019.06.011.

6. In a 480-patient, four-arm, multicenter randomized phase 2/3 trial, none of three orthobiologic cell injections - autologous bone marrow aspirate concentrate, autologous adipose stromal vascular fraction, or allogeneic umbilical cord tissue-derived mesenchymal stromal cells - was superior to any other, or to a corticosteroid injection control, on pain at 12 months.

   Mautner K, et al. — Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial. Nat Med, 2023. DOI: 10.1038/s41591-023-02632-w.